

# Product Datasheet

## HOXC11 Antibody (OTI3E10)

### NBP2-00499

Unit Size: 0.1 ml

Store at -20C. Avoid freeze-thaw cycles.

[www.novusbio.com](http://www.novusbio.com)



[technical@novusbio.com](mailto:technical@novusbio.com)

#### Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:  
[www.novusbio.com/NBP2-00499](http://www.novusbio.com/NBP2-00499)

Updated 9/9/2025 v.20.1

Earn rewards for product  
reviews and publications.

Submit a publication at [www.novusbio.com/publications](http://www.novusbio.com/publications)

Submit a review at [www.novusbio.com/reviews/destination/NBP2-00499](http://www.novusbio.com/reviews/destination/NBP2-00499)



**NBP2-00499**

HOXC11 Antibody (OTI3E10)

Product Information	
Unit Size	0.1 ml
Concentration	0.44 mg/ml
Storage	Store at -20C. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	OTI3E10
Preservative	0.02% Sodium Azide
Isotype	IgG1
Purity	Immunogen affinity purified
Buffer	PBS (pH 7.3), 1.0% BSA and 50% Glycerol
Target Molecular Weight	33.6 kDa


Product Description	
Description	Novus Biologicals Mouse HOXC11 Antibody (OTI3E10) (NBP2-00499) is a monoclonal antibody validated for use in IHC, WB, Flow and ICC/IF. Anti-HOXC11 Antibody: Cited in 2 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Mouse
Gene ID	3227
Gene Symbol	HOXC11
Species	Human, Mouse, Rat
Reactivity Notes	Please note that this antibody is reactive to Mouse and derived from the same host, Mouse. Mouse-On-Mouse blocking reagent may be needed for IHC and ICC experiments to reduce high background signal. You can find these reagents under catalog numbers PK-2200-NB and MP-2400-NB. Please contact Technical Support if you have any questions.
Immunogen	Human recombinant protein fragment corresponding to amino acids 1-304 of human HOXC11(NP_055027) produced in E.coli.

Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry
Recommended Dilutions	Western Blot 1:500-2000, Flow Cytometry 1:100, Immunohistochemistry 1:150, Immunocytochemistry/ Immunofluorescence 1:100, Immunohistochemistry-Paraffin 1:150




## Images


Western Blot: HOXC11 Antibody (3E10) [NBP2-00499] - Analysis of extracts (10ug) from 9 Human tissue by using anti-HOXC11 monoclonal antibody at 1:200 (1: Testis; 2: Omentum; 3: Uterus; 4: Breast; 5: Brain; 6: Liver; 7: Ovary; 8: Thyroid gland; 9: colon)




Immunocytochemistry/Immunofluorescence: HOXC11 Antibody (3E10) [NBP2-00499] Staining of COS7 cells transiently transfected by pCMV6-ENTRY HOXC11.




Immunohistochemistry-Paraffin: HOXC11 Antibody (3E10) [NBP2-00499] - Staining of paraffin-embedded Human tonsil using anti-HOXC11 mouse monoclonal antibody.




Flow Cytometry: HOXC11 Antibody (3E10) [NBP2-00499] - HEK293T cells transfected with either overexpression plasmid (Red) or empty vector control plasmid (Blue) were immunostained by anti-HOXC11 antibody, and then analyzed by flow cytometry.




Western Blot: HOXC11 Antibody (3E10) [NBP2-00499] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY HOXC11 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-HOXC11.




Western Blot: HOXC11 Antibody (3E10) [NBP2-00499] - Analysis of extracts (10ug) from a mouse cell line and 3 different mouse tissues by using antiHOXC11 monoclonal antibody.(1:200)




Immunohistochemistry-Paraffin: HOXC11 Antibody (3E10) [NBP2-00499] - Staining of paraffin-embedded Adenocarcinoma of Human breast tissue using anti-HOXC11 mouse monoclonal antibody.




Immunohistochemistry-Paraffin: HOXC11 Antibody (3E10) [NBP2-00499] - Staining of paraffin-embedded Adenocarcinoma of Human colon tissue using anti-HOXC11 mouse monoclonal antibody.




Immunohistochemistry-Paraffin: HOXC11 Antibody (3E10) [NBP2-00499] - Staining of paraffin-embedded Carcinoma of Human bladder tissue using anti-HOXC11 mouse monoclonal antibody.




Immunohistochemistry-Paraffin: HOXC11 Antibody (3E10) [NBP2-00499] - Staining of paraffin-embedded Human endometrium tissue using anti-HOXC11 mouse monoclonal antibody.




HOXC11 binds to the promoter of SPHK1 to facilitate its expression, predicting a worse prognosis. a GSEA analyzed potential binding targets of HOXC11. b qPCR analysis of CCL5, HBA2, and SPHK1 expression level after stable overexpression of HOXC11. Data are shown as mean  $\pm$  SD (n = 3). c Western Blot analysis of SPHK1 protein expression level after HOXC11 stable overexpression. d Western Blot analysis of SPHK1 protein expression level after HOXC11 knockout. e Relative enrichment of SPHK1 promoter in HOXC11 stable overexpressing cells. Data are shown as mean  $\pm$  SD (n = 3). f Western Blot detected SPHK1 protein expression of HOXC11 knockout cells and that after transiently transfected with 1.5  $\mu$ g HOXC11 expression plasmid. NS not significant, \*P < 0.05, \*\*P < 0.01. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




HOXC11 is highly expressed in lung adenocarcinoma and correlates with poor overall survival of LUAD. a A heatmap of mRNA level of HOXC family genes in LUAD/LUSC and paracancerous samples. b mRNA level of HOXC11 in LUAD/LUSC and paracancerous samples. Data in (a) and (b) are obtained from the TCGA database. c HOXC11 protein expression in LUAD/LUSC and paracancerous tissues. d The relationship between HOXC11 expression and overall survival of lung cancer patients. e The relationship between HOXC11 expression and overall survival of LUAD patients. f The relationship between HOXC11 expression and gender of lung cancer patients. g The relationship between HOXC11 expression and smoking habits of lung cancer patients. Data from (d) to (g) come from the Kaplan–Meier Plotter lung cancer dataset. \*\*\*P < 0.001, \*\*\*\*P < 0.0001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




HOXC11 binds to the promoter of SPHK1 to facilitate its expression, predicting a worse prognosis. a GSEA analyzed potential binding targets of HOXC11. b qPCR analysis of CCL5, HBA2, and SPHK1 expression level after stable overexpression of HOXC11. Data are shown as mean  $\pm$  SD (n = 3). c Western Blot analysis of SPHK1 protein expression level after HOXC11 stable overexpression. d Western Blot analysis of SPHK1 protein expression level after HOXC11 knockout. e Relative enrichment of SPHK1 promoter in HOXC11 stable overexpressing cells. Data are shown as mean  $\pm$  SD (n = 3). f Western Blot detected SPHK1 protein expression of HOXC11 knockout cells and that after transiently transfected with 1.5  $\mu$ g HOXC11 expression plasmid. NS not significant, \*P < 0.05, \*\*P < 0.01. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




SPHK1 accelerates the progression of lung cancer. a Cell proliferation ability of SPHK1 stable overexpressed cells detected by cell counting kit-8. Data are shown as mean  $\pm$  SD (n = 5). b Colony formation assays showing the colony formatted ability of SPHK1 stable overexpressed cells and the quantitative analyses. Data are shown as mean  $\pm$  SD (n = 3). c Cell migration and invasion ability of SPHK1 stable overexpressed cells detected by Transwell assays and the quantitative analyses. Data are shown as mean  $\pm$  SD (n = 3). d Flow cytometry detecting the cell cycle of SPHK1 overexpressed cells. Differences are compared with the sgCtrl group; data are shown as mean  $\pm$  SD (n = 3). e Western blot detected the SPHK1 protein level of HOXC11 overexpressing cells with the treatment of SPHK1 interference. f Cell counting kit-8 detected the cell viability of HOXC11 overexpressing cell line with the treatment of SPHK1 interference. Data are shown as mean  $\pm$  SD (n = 5). g Transwell assays detected the migration and invasion ability of HOXC11 overexpressing cell line with the treatment of SPHK1 interference and the quantitative analyses. Differences were compared to the Vector group transfected with Ctrl siRNA. Data are shown as mean  $\pm$  SD (n = 3). NS not significant, \*P < 0.05, \*\*P < 0.01, \*\*\* P < 0.001, \*\*\*\*P < 0.0001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




HOXC11 binds to the promoter of SPHK1 to facilitate its expression, predicting a worse prognosis. a GSEA analyzed potential binding targets of HOXC11. b qPCR analysis of CCL5, HBA2, and SPHK1 expression level after stable overexpression of HOXC11. Data are shown as mean  $\pm$  SD (n = 3). c Western Blot analysis of SPHK1 protein expression level after HOXC11 stable overexpression. d Western Blot analysis of SPHK1 protein expression level after HOXC11 knockout. e Relative enrichment of SPHK1 promoter in HOXC11 stable overexpressing cells. Data are shown as mean  $\pm$  SD (n = 3). f Western Blot detected SPHK1 protein expression of HOXC11 knockout cells and that after transiently transfected with 1.5  $\mu$ g HOXC11 expression plasmid. NS not significant, \*P < 0.05, \*\*P < 0.01. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



IKK $\alpha$  regulates HOXC11 expression at the post-transcriptional level. a Western Blot showed the up-regulation of HOXC11 resulting from IKK $\alpha$  stable overexpression. b Western Blot detected the down-regulation of HOXC11 resulting from the IKK $\alpha$  knockout. c qPCR analysis of HOXC11 mRNA level after stable overexpression of IKK $\alpha$ . Data are shown as mean  $\pm$  SD (n = 3). d Western Blot showing HOXC11 protein cumulation after treatment with MG132 (10  $\mu$ M, 24 h). e Western Blot showed HOXC11 protein degradation after treatment with cycloheximide (10  $\mu$ g/ml). f Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  stable overexpression and MG132 treatment (20  $\mu$ M, 12 h). g Western Blot showed HOXC11 protein expression after IKK $\alpha$  stable overexpression and treatment with cycloheximide (20  $\mu$ g/ml). h Western Blot analysis of HOXC11 accumulation after IKK $\alpha$  knockout and MG132 treatment (20  $\mu$ M, 10 h). i Western Blot showed HOXC11 protein expression after IKK $\alpha$  knockout and treatment with cycloheximide (20  $\mu$ g/ml). j Ubiquitinating and deubiquitinating enzymes of HOXC11 and IKK $\alpha$  predicted by UbiBrowser 2.0. USP8 is shared by HOXC11 and IKK $\alpha$ . k USP8 with tag-Myc was instantaneously expressed in HEK293T, and Western Blot detected the protein level of IKK $\alpha$  and HOXC11. l Immunofluorescence detected the localization of IKK $\alpha$  (red) relative to HOXC11 (green) or Myc-USP8 (green) in PC9 cells. Scale bars, 20  $\mu$ m. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36823149>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



## Publications

Peng X, Liu X, Hu W et al. HOXC11 drives lung adenocarcinoma progression through transcriptional regulation of SPHK1 Cell death & disease 2023-02-23 [PMID: 36823149] (Western Blot, Immunocytochemistry/Immunofluorescence, Human)

Peng X, Sun J, Long Y et al. The Significance of HOXC11 and LSH in Survival Prediction in Gastric Adenocarcinoma OncoTargets and therapy 2021-03-01 [PMID: 33688200] (IF/IHC, WB, Human)



### **Novus Biologicals USA**

10730 E. Briarwood Avenue  
Centennial, CO 80112  
USA  
Phone: 303.730.1950  
Toll Free: 1.888.506.6887  
Fax: 303.730.1966  
nb-customerservice@bio-techne.com

### **Bio-Techne Canada**

21 Canmotor Ave  
Toronto, ON M8Z 4E6  
Canada  
Phone: 905.827.6400  
Toll Free: 855.668.8722  
Fax: 905.827.6402  
canada.inquires@bio-techne.com

### **Bio-Techne Ltd**

19 Barton Lane  
Abingdon Science Park  
Abingdon, OX14 3NB, United Kingdom  
Phone: (44) (0) 1235 529449  
Free Phone: 0800 37 34 15  
Fax: (44) (0) 1235 533420  
info.EMEA@bio-techne.com

### **General Contact Information**

www.novusbio.com  
Technical Support: nb-technical@bio-techne.com  
Orders: nb-customerservice@bio-techne.com  
General: novus@novusbio.com

### **Products Related to NBP2-00499**

---

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF007	Goat anti-Mouse IgG Secondary Antibody [HRP]
NB7539	Goat anti-Mouse IgG (H+L) Secondary Antibody [HRP]
NBP1-97005-0.5mg	Mouse IgG1 Isotype Control (MG1)

---

### **Limitations**

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit [www.novusbio.com/guarantee](http://www.novusbio.com/guarantee)

Earn gift cards/discounts by submitting a review: [www.novusbio.com/reviews/submit/NBP2-00499](http://www.novusbio.com/reviews/submit/NBP2-00499)

Earn gift cards/discounts by submitting a publication using this product:  
[www.novusbio.com/publications](http://www.novusbio.com/publications)

